Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Disc Degeneration: Intradiscal vs IV
Transcript
- 0:00SPEAKER_00: Welcome to the Cybernusel Podcast.
- 0:03SPEAKER_01: You know, I was thinking about the instinct you have when you see like a cracked foundation in a house or maybe a pothole in the road.
- 0:09SPEAKER_00: Oh yeah, the immediate need to just patch it up.
- 0:11SPEAKER_01: Yeah, exactly.
- 0:12SPEAKER_01: The human brain kind of defaults to this very specific civil engineering logic.
- 0:16SPEAKER_00: Yeah.
- 0:17SPEAKER_01: You find the hole and you mix up some concrete and you pour it directly into the gap to fix the problem.
- 0:22SPEAKER_00: Which makes total sense for a driveway.
- 0:24SPEAKER_01: But we want to do the exact same thing with the human body.
- 0:26SPEAKER_01: Like when you have a degenerating disc in your spine causing you just absolute agony, the most intuitive thought in the world is to take a needle full of regenerative cells and drive it straight into that damaged disc to fill the pothole.
- 0:40SPEAKER_00: I mean, it is incredibly seductive logic.
- 0:43SPEAKER_00: The idea that we can just operate like mechanics and identify a worn-out biological part and physically inject a repair patch directly into the center of the damage.
- 0:52SPEAKER_01: It feels like it should be the ultimate solution.
- 0:54SPEAKER_01: It really does.
- 0:56SPEAKER_01: But the deeper we look at the cellular reality of the human spine, the more that civil engineering mindset starts to fall apart.
- 1:03SPEAKER_01: Biology just rarely respects our desire for simple mechanical fixes.
- 1:08SPEAKER_00: And today we are putting that mindset under the microscope.
- 1:11SPEAKER_00: We've got a really fascinating stack of clinical research and commentaries and systematic reviews focused on how we actually deliver these regenerative therapies.
- 1:20SPEAKER_01: It is a critical distinction that I think a lot of people miss when they start researching this stuff.
- 1:24SPEAKER_00: Yeah, so our mission for this deep dive is to unpack the central choice in this field.
- 1:29SPEAKER_00: We are evaluating the evidence behind 5e stem cell therapy for disc degeneration and comparing it to that traditional approach of injecting those cells directly into the spinal disc.
- 1:38SPEAKER_01: Aaron Powell Because the delivery method completely changes the biological mechanism.
- 1:42SPEAKER_00: Exactly.
- 1:43SPEAKER_00: The goal here is to help you look past the marketing and understand the actual biomechanics at play so you can grasp the very real trade-offs and make informed decisions about your own care.
- 1:53SPEAKER_01: Well, we do need to set a firm boundary on expectations before we even dive into the mechanism.
- 1:58SPEAKER_00: Oh, for sure.
- 1:58SPEAKER_01: We are dealing with cutting-edge medical science here, but we are absolutely not talking about magic.
- 2:04unknown: Right.
- 2:05SPEAKER_01: Whether we look at direct injections or intravenous drips, there is no current therapy in existence that completely reverses degenerative disc disease.
- 2:13SPEAKER_00: Aaron Powell We are not growing you a brand new spine.
- 2:15SPEAKER_01: We are not.
- 2:16SPEAKER_01: We are talking about fundamentally altering the inflammatory environment and managing chronic pain.
- 2:23SPEAKER_01: So if you go into this literature expecting like a structural time machine, you will fundamentally misunderstand what the clinical data is actually telling us.
- 2:32SPEAKER_00: Aaron Powell So let us start by painting a vivid picture of the two delivery routes because they represent entirely different philosophies of medicine.
- 2:38SPEAKER_00: First, you have the intradiscal injection.
- 2:40SPEAKER_01: The direct approach.
- 2:41SPEAKER_00: Yeah.
- 2:42SPEAKER_00: The physician uses fluoroscopy to guide a spinal needle directly into the center of your damaged disc.
- 2:47SPEAKER_01: They are specifically targeting the nucleus pulpusis, which is that pressurized gel-like core.
- 2:52SPEAKER_00: Aaron Powell And they deposit a concentration of mesenchymal stem cells or MSCs straight into the epicenter of the structural damage.
- 2:59SPEAKER_01: And then the alternative to that is the systemic intravenous or IV infusion.
- 3:03SPEAKER_00: Which is much simpler, practically speaking.
- 3:06SPEAKER_01: Oh yeah.
- 3:06SPEAKER_01: In this scenario, a nurse simply places a standard drip line into a peripheral vein in your arm.
- 3:12SPEAKER_00: Aaron Powell Like getting fluids or a vitamin drip.
- 3:15SPEAKER_01: Exactly like that.
- 3:17SPEAKER_01: The MSCs are introduced into your global bloodstream over the course of about an hour.
- 3:22SPEAKER_01: There is no fluoroscopy.
- 3:24SPEAKER_00: And no spinal needle.
- 3:25SPEAKER_01: No spinal needle at all.
- 3:27SPEAKER_01: The cells enter global circulation rather than being trapped in one specific local compartment.
- 3:33SPEAKER_00: You know, when I was reading through the clinical literature, a specific analogy kept coming to my mind.
- 3:37SPEAKER_01: What was that?
- 3:37SPEAKER_00: The interdiscal injection is essentially like parachuting troops directly onto a specific battlefield.
- 3:43SPEAKER_00: Okay.
- 3:44SPEAKER_00: I like that.
- 3:44SPEAKER_00: You are dropping them directly into the hot zone and just assuming they will pull out their shovels and start physically rebuilding the local terrain.
- 3:51SPEAKER_00: Yes.
- 3:51SPEAKER_00: But the IV delivery is entirely different.
- 3:55SPEAKER_00: It is like sending diplomats into the global transit system.
- 3:58SPEAKER_01: That actually captures the mechanistic difference beautifully.
- 4:01SPEAKER_01: The intradiscal approach, your paratroopers, is rooted in the theory of local engraftment.
- 4:07SPEAKER_00: Meaning they physically plant themselves there.
- 4:09SPEAKER_01: Yeah.
- 4:09SPEAKER_01: The assumption is that by forcing the cells into the defect, they will take root and differentiate into cartilage-like cells to reconstruct the tissue.
- 4:18SPEAKER_00: And the diplomats.
- 4:19SPEAKER_01: The AVI approach relies on peracrine signaling.
- 4:22SPEAKER_01: Because those cells are circulating in the blood, they do not need to make physical contact with the damaged disc cartilage.
- 4:29SPEAKER_00: Which is wild to think about.
- 4:30SPEAKER_01: It is, but instead of acting like builders, they act as cellular communicators.
- 4:35SPEAKER_01: They detect inflammatory markers in the bloodstream, and in response, they release these microscopic packets of proteins and growth factors called exosomes.
- 4:43SPEAKER_00: So they are sending messages.
- 4:45SPEAKER_01: Exactly.
- 4:45SPEAKER_01: They were rewriting the chemical rules of engagement.
- 4:48SPEAKER_01: They instruct your own immune system to stop attacking the tissue and start prioritizing repair.
- 4:53SPEAKER_00: But hold on a second.
- 4:54SPEAKER_00: If I am looking at my own MRI and I see a specific dark compressed disc at like L4, L5 slab that is causing my sciatic.
- 5:03SPEAKER_01: Your classic trouble spot.
- 5:04SPEAKER_00: Yeah, why would I ever want diplomats circulating in my arm?
- 5:07SPEAKER_00: I mean, I want the paratroopers.
- 5:08SPEAKER_01: You want the localized fix?
- 5:09SPEAKER_00: Yes.
- 5:10SPEAKER_00: The civil engineering logic is screaming at me that direct application just has to be superior.
- 5:15SPEAKER_01: And that exact debate is what prompted a really highly scrutinized 2014 study where researchers tested this very question side by side, but they did it in animal models.
- 5:27SPEAKER_00: They took mice with induced disc degeneration and literally split them up.
- 5:32SPEAKER_01: Right.
- 5:32SPEAKER_01: One group received the direct intradiscal injection, and the other group received the systemic IV delivery.
- 5:37SPEAKER_00: Aaron Powell Because they wanted to see strictly by the data which strategy actually yielded a better biological outcome.
- 5:43SPEAKER_01: And the results were genuinely mixed, which is what makes this so interesting.
- 5:47SPEAKER_00: Aaron Powell Yeah.
- 5:47SPEAKER_00: For the mice that received the intradiscal injection, the paratroopers actually kind of did their job.
- 5:53SPEAKER_01: They did.
- 5:54SPEAKER_01: The researchers observed that direct injection helped preserve the height of the disc, and it visibly slowed the structural markers of degeneration.
- 6:02SPEAKER_00: So the physical architecture held up better in the spine.
- 6:04SPEAKER_01: But the IV group presented a fascinating biological puzzle.
- 6:08SPEAKER_01: The IV delivery did not preserve the disc height to the same robust degree as the direct injection.
- 6:14SPEAKER_00: Which makes sense mechanically.
- 6:16SPEAKER_01: But the systemic route triggered a significant increase in specific extracellular matrix proteins.
- 6:22SPEAKER_01: We are talking about things like agricon and collagen type 2.
- 6:26SPEAKER_00: And those are important.
- 6:27SPEAKER_00: Why?
- 6:28SPEAKER_01: Because those proteins are the vital scaffolding that hold water inside the disc.
- 6:34SPEAKER_01: They give it its shock-absorbing power.
- 6:36SPEAKER_00: And this happened without the stem cells ever physically touching the disc.
- 6:40SPEAKER_01: Precisely the point.
- 6:41SPEAKER_01: The systemic delivery was still sending potent chemical signals that promoted a local healing response and matrix production, but entirely through indirect systemic communication.
- 6:52SPEAKER_00: So you have to push back here though, because we see these same patterns replicated in rats and rabbits too.
- 6:58SPEAKER_01: We do, yeah.
- 6:58SPEAKER_00: The direct injection consistently shows better structural preservation in the animal's spine.
- 7:03SPEAKER_01: It does.
- 7:04SPEAKER_00: So if intradiscal delivery actually preserves disc height in these models, doesn't that make it the undisputed heavyweight champion?
- 7:11SPEAKER_01: You would think so.
- 7:11SPEAKER_00: I mean, if I can prevent my disc from collapsing by dropping cells directly into it, why are we even discussing the IV route?
- 7:17SPEAKER_00: Like case close, bring out the spinal needle.
- 7:20SPEAKER_01: Because you are not a mouse.
- 7:22SPEAKER_00: Okay, fair point.
- 7:23SPEAKER_01: Translating the biomechanics of a tiny quadrupedal animal to a bipedal human that has been carrying decades of mechanical load, it changes the entire biological equation.
- 7:33SPEAKER_00: The forces are just completely different.
- 7:35SPEAKER_01: Entirely different.
- 7:36SPEAKER_01: When we inject cells into a human spine, we are sending them into one of the most hostile, unforgiving environments in the entire human body.
- 7:45SPEAKER_00: Yeah, I was trying to visualize the environment inside a degenerated human disc earlier.
- 7:50SPEAKER_00: It is not just a damaged piece of meat.
- 7:53SPEAKER_01: No, it is much harsher.
- 7:54SPEAKER_00: It is more like a deep sea trench or like a sealed high-pressure submarine resting at the bottom of the ocean.
- 8:00SPEAKER_01: That is a great way to picture it.
- 8:02SPEAKER_01: It is a vascular, which means it has virtually no blood vessels supplying it with nutrients.
- 8:07SPEAKER_00: So nothing is feeding it.
- 8:08SPEAKER_01: And it is severely hypoxic, meaning there's almost zero oxygen in there.
- 8:12SPEAKER_01: The pH level is highly acidic, too.
- 8:14SPEAKER_00: And because you walk on two legs, it is under this constant crushing hydrostatic pressure.
- 8:19SPEAKER_01: Right.
- 8:19SPEAKER_01: There's a 2022 commentary published in NPJ Regenerative Medicine that focused heavily on this exact reality.
- 8:26SPEAKER_00: A hostile environment?
- 8:27SPEAKER_01: Yes.
- 8:28SPEAKER_01: The paratroopers you are dropping into this environment are incredibly fragile living cells.
- 8:34SPEAKER_01: So when you force them into an acidic, oxygen-starved high-pressure vault, their survival rate just plummets.
- 8:41SPEAKER_00: They just die off.
- 8:42SPEAKER_01: It is exceptionally difficult for them to stay alive long enough to engineer any meaningful tissue reconstruction.
- 8:48SPEAKER_00: And then there is a 2025 systematic review in the North American Spine Society Journal that heavily reinforced this rate.
- 8:56SPEAKER_01: Yeah, it noted that the fundamental hostility of the human disc makes local engraftment just a massive clinical hurdle.
- 9:03SPEAKER_00: Which means hoping the cells stick around and grow is kind of a long shot.
- 9:07SPEAKER_01: And the review pointed out that current human trials have methodological weaknesses, making it genuinely dangerous to draw firm conclusions based solely on that optimistic animal data.
- 9:17SPEAKER_00: Which brings us to a concept in the research that completely flipped my perspective on this whole debate.
- 9:21SPEAKER_01: The procedural risk.
- 9:22SPEAKER_00: Yeah, because the survival of the cells is only half the problem.
- 9:26SPEAKER_00: The other half is how you actually get them into the submarine.
- 9:29SPEAKER_01: Ah, the needle paradox.
- 9:31SPEAKER_01: This is perhaps the most critical concept for anyone considering this therapy to understand.
- 9:36SPEAKER_01: To deliver cells directly into the center of your disc, the physician must drive a needle through the annulus fibrosis.
- 9:44SPEAKER_00: Which is the tough fibrous outer ring that holds the pressurized gel inside.
- 9:49SPEAKER_01: Yes.
- 9:49SPEAKER_00: So you basically have to puncture the steel belt of the tire just to put the patch on the inside.
- 9:54SPEAKER_01: And in doing so, you are structurally compromising an already failing component.
- 9:58SPEAKER_00: That seems counterproductive.
- 10:00SPEAKER_01: It is.
- 10:00SPEAKER_01: The human disc relies on strict hydrostatic pressure to function.
- 10:05SPEAKER_01: The very act of puncturing that outer ring with a needle carries a documented genuine risk of accelerating the exact degenerative cascade you are attempting to treat.
- 10:14SPEAKER_00: So you are creating a new defect in the outer wall.
- 10:16SPEAKER_01: Which could lead to further pressure loss and further biomechanical instability.
- 10:20SPEAKER_00: An accelerated breakdown of the disc.
- 10:22SPEAKER_00: The cure actively risks worsening the disease.
- 10:25SPEAKER_01: It is a profound irony in spine medicine.
- 10:27SPEAKER_00: When you understand that specific trade-off, the desire for direct cellular contact versus the genuine physical risk of stabbing a failing structure, you start to see why specialized clinics make very deliberate choices about their protocols.
- 10:42SPEAKER_01: They have to weigh those risks every day.
- 10:44SPEAKER_00: Like we can look at Cironacell as a prime example of how this science is applied in the real world.
- 10:49SPEAKER_00: They operate out of Kuala Lumpur and they deal with a vast array of really complex cases.
- 10:54SPEAKER_01: And they see a very diverse demographic.
- 10:56SPEAKER_00: Oh, absolutely.
- 10:57SPEAKER_00: They treat local patients, but they also have a massive international footprint.
- 11:01SPEAKER_00: Patients are regularly flying in from Australia and the Middle East and beyond.
- 11:05SPEAKER_01: And their clinical protocol is highly, highly specific.
- 11:08SPEAKER_01: They utilize Wharton's jelly, mesenchinyl, stem cells, WGMSEs.
- 11:13SPEAKER_00: Which are derived from the umbilical cord, right?
- 11:16SPEAKER_01: Correct.
- 11:16SPEAKER_01: But the defining characteristic of their approach, based on the biomechanics we were discussing, is their absolute reliance on the IV route.
- 11:24SPEAKER_00: Trevor Burrus, meaning they don't do the spinal injections.
- 11:25SPEAKER_00: Trevor Burrus, Jr.
- 11:25SPEAKER_01: Sarona cell exclusively uses intravenous administration for these cases.
- 11:30SPEAKER_01: They completely reject the intradiscal injection.
- 11:32SPEAKER_01: Trevor Burrus, Jr.
- 11:32SPEAKER_00: Which makes sense because by choosing the IV route, they entirely eliminate the needle paradox.
- 11:38SPEAKER_01: Gone.
- 11:39SPEAKER_00: There is zero risk of puncturing the disc and zero risk of creating a new structural defect.
- 11:44SPEAKER_01: And zero risk of accelerating the mechanical collapse through a procedural injury.
- 11:48SPEAKER_00: It is a very calculated pivot in biological strategy.
- 11:51SPEAKER_01: Aaron Powell They are looking at the hostile environment of the disc and looking at the risks of the spinal needle and intentionally choosing to prioritize systemic anti-inflammatory modulation over local tissue engineering.
- 12:05SPEAKER_00: They are operating on the premise that calming the aggressive immune activity that drives the breakdown of the cartilage is just a much safer path.
- 12:13SPEAKER_01: Aaron Powell A safer and more sustainable path than risking further physical damage to force cells into an acidic vault where they will probably die anyway.
- 12:19SPEAKER_00: Aaron Powell But I do want to challenge the biology of that systemic strategy, though.
- 12:23SPEAKER_01: Okay, go for it.
- 12:24SPEAKER_00: So if we establish that the human disc is a sealed submarine with no blood supply, how did the intravenous diplomats even reach the problem?
- 12:32SPEAKER_01: This is a very valid question.
- 12:32SPEAKER_00: Aaron Powell Because if the IV cells circulate in the blood, but the disc has no blood vessels, aren't we just giving these patients like highly sophisticated systemic ibuprofen?
- 12:42SPEAKER_01: Aaron Powell It sounds like it irrelevant.
- 12:44SPEAKER_00: Yeah, how do we know the anti-inflammatory effect actually reaches the spine?
- 12:47SPEAKER_01: Aaron Powell Okay, so the disc itself is a vascular, but the pain you feel does not exist in a vacuum.
- 12:53SPEAKER_00: What do you mean?
- 12:54SPEAKER_01: The inflammatory cytokines, the chemical signals that are actually causing your agony, they're not locked inside the disc.
- 13:01SPEAKER_00: They leak out.
- 13:02SPEAKER_01: They leak out and they bathe the surrounding epidural space.
- 13:05SPEAKER_01: They inflame the local vascular network at the margins of the vertebrae.
- 13:09SPEAKER_00: So the area around the disc is highly vascular.
- 13:11SPEAKER_01: Exactly.
- 13:12SPEAKER_01: And most importantly, they heavily irritate the dorsal root ganglion, which is the major cluster of nerves sitting right next to the disc.
- 13:19SPEAKER_00: So the IV cells don't actually need to get inside the submarine?
- 13:23SPEAKER_01: They do not need to penetrate the avascular center of the disc to do their job.
- 13:27SPEAKER_01: They circulate through the blood-rich tissues surrounding the spine.
- 13:30SPEAKER_00: Binding to those pro-inflammatory markers.
- 13:33SPEAKER_01: And releasing their anti-inflammatory exosomes right into that local neighborhood.
- 13:37SPEAKER_00: Oh, I see.
- 13:38SPEAKER_00: They calm the chemical fire, burning the nerves outside the disc.
- 13:41SPEAKER_00: Aaron Powell, Jr.
- 13:41SPEAKER_01: Which is what actually provides the pain relief.
- 13:43SPEAKER_00: So for the patient making that like eight-hour flight from Sydney to Kuala Lumpur, this is a really profound exercise in risk tolerance and biological philosophy.
- 13:53SPEAKER_01: It really is.
- 13:54SPEAKER_00: You have to decide if you are comfortable risking a spinal puncture for the theoretical hope of structural regrowth, or if you prefer a safety-first strategy that focuses entirely on neutralizing the inflammatory environment driving your pain.
- 14:08SPEAKER_01: It requires a massive shift in how patients measure success.
- 14:11SPEAKER_00: No, so.
- 14:12SPEAKER_01: If we look at the clinical trial evidence for regenerative therapies over a six to twelve month horizon, the outcomes heavily favor the systemic model of success.
- 14:21SPEAKER_00: Aaron Powell So the data backs up the symptom relief.
- 14:23SPEAKER_01: Yes.
- 14:24SPEAKER_01: Whether a trial utilizes direct injection or IV delivery, the primary endpoints that actually improve are pain scores and functional mobility metrics.
- 14:32SPEAKER_00: Meaning the patient feels significantly less pain and can suddenly like bend over to tie their shoes or walk without a limp.
- 14:39SPEAKER_01: But if you take that same highly functional pain-free patient and put them back inside an MRI machine 12 months later, you will rarely see a beautifully regenerated, plump, youthful disc on the scan.
- 14:53SPEAKER_00: The structural regrowth just isn't there.
- 14:55SPEAKER_01: Visible structural regrowth on imaging is exceptionally rare across the board, regardless of the delivery route.
- 15:01SPEAKER_00: So the therapy modifies the symptoms of the disease and alters the chemical environment, but it does not mechanically reverse the aging of the tissue.
- 15:09SPEAKER_01: That is the reality of the current science.
- 15:11SPEAKER_00: Meaning if I have a mulging desk at L55 pressing on a nerve, an IV infusion of WJMSCs is not going to reach into my spine and physically pull that bulge back into place.
- 15:24SPEAKER_01: You will not retract a mechanical bulge.
- 15:26SPEAKER_00: But it can dramatically reduce the swelling and inflammation and the hypersensitivity of the nerve being pressed by that bulge.
- 15:35SPEAKER_00: And I think the safety profiles really drive this decision matrix home for a lot of people.
- 15:39SPEAKER_01: They are drastically different profiles.
- 15:42SPEAKER_00: Yeah.
- 15:42SPEAKER_00: When we talk about the risks of intradiscal injection, we aren't just talking about the needle paradox and accelerated degeneration.
- 15:49SPEAKER_01: No, you have immediate procedural risks.
- 15:52SPEAKER_00: Anytime a physician drives a needle deep into the spinal architecture, you introduce the risk of decitis.
- 15:58SPEAKER_01: Which is a severe infection inside the disc space.
- 16:01SPEAKER_00: Along with the potential for direct nerve root trauma or epidural hematomas.
- 16:05SPEAKER_01: Compare that to the safety data for intravenous delivery, particularly with the umbilical cord sources cybernosil uses.
- 16:12SPEAKER_00: Which have a very robust early safety profile.
- 16:15SPEAKER_01: Very robust.
- 16:16SPEAKER_01: The risks associated with the IV route are vastly milder.
- 16:20SPEAKER_01: You are looking at standard systemic infusion reactions.
- 16:24SPEAKER_00: Like what specifically?
- 16:25SPEAKER_01: A patient might experience a transient mild fever, maybe a headache, or just temporary discomfort at the injection site on their arm.
- 16:31SPEAKER_00: But the procedural risk to the actual spinal column is literally zero.
- 16:35SPEAKER_01: Literally zero.
- 16:37SPEAKER_00: But we still have to be diligent about this.
- 16:38SPEAKER_00: A safer procedural route does not mean everyone gets a free pass on medical screening.
- 16:43SPEAKER_01: Oh, absolutely not.
- 16:44SPEAKER_01: Patient selection is everything.
- 16:45SPEAKER_00: The patient still needs comprehensive blood work.
- 16:48SPEAKER_00: They need recent MRI or CT scans reviewed by the clinical team.
- 16:52SPEAKER_01: They need a deep dive into their specific symptom history.
- 16:56SPEAKER_00: Because you have to prove that your specific mechanical pain is actually being driven by an inflammatory cascade that the stem cells can target.
- 17:04SPEAKER_01: Which defines the ideal candidate for this type of intervention perfectly.
- 17:08SPEAKER_00: So what does the data say about who actually responds best?
- 17:12SPEAKER_01: The data indicates that patients with early to moderate degenerative changes respond the best.
- 17:18SPEAKER_00: Not the most severe cases.
- 17:20SPEAKER_01: No.
- 17:21SPEAKER_01: If a patient has severe spinal collapse or bone-on-bone grinding or profound spinal instability, the biological signaling of stem cells will struggle to overcome that sheer mechanical failure.
- 17:33SPEAKER_00: Right.
- 17:33SPEAKER_00: If the house is already collapsed, putting up the fire doesn't rebuild the walls.
- 17:36SPEAKER_01: Exactly.
- 17:37SPEAKER_00: So the sweet spot is the patient who has kind of exhausted the conservative playbook.
- 17:41SPEAKER_00: Yes.
- 17:42SPEAKER_00: Like you have done the physical therapy, you have taken the NSAAIDs, you have tried the standard corticosteroid injections, and the pain just keeps coming back.
- 17:50SPEAKER_01: You are staring down the barrel of a spinal fusion, and you are looking for a biological intervention to delay or entirely avoid that surgery.
- 17:59SPEAKER_00: It really forces a highly personal choice when you are in that position.
- 18:03SPEAKER_01: It does.
- 18:04SPEAKER_01: You have to abandon the simple civil engineering mindset.
- 18:06SPEAKER_00: You realize you are not just filling a pothole, you are managing a complex, hostile biological ecosystem.
- 18:13SPEAKER_01: And you have to weigh your personal anxiety about spinal needles against the milder profile of an IV drip.
- 18:19SPEAKER_00: You have to balance the animal model promises of direct tissue contact against the reality of the human needle paradox.
- 18:26SPEAKER_01: It is about aligning the mechanism of the treatment with your own clinical reality.
- 18:31SPEAKER_00: You choose the diplomats when you recognize that calming the systemic fire is just a much more sustainable path than dropping paratroopers into a pressurized trench.
- 18:40SPEAKER_01: And you know, stepping back to look at the sheer biological capability of those intravenously delivered diplomats introduces a fascinating layer to this entire discussion.
- 18:49SPEAKER_00: Aaron Powell What do you mean?
- 18:50SPEAKER_01: Well, we know that IV-delivered MSCs circulate through the global bloodstream.
- 18:54SPEAKER_01: We know they actively hunt for and respond to pro-inflammatory signaling.
- 18:59SPEAKER_00: Yeah, they act as roaming cellular pharmacies.
- 19:02SPEAKER_01: Consider the implications of that mechanism for a second.
- 19:05SPEAKER_01: If a patient receives this systemic IV treatment primarily to address the agonizing inflammation around their degenerating lower back, those cells are still circulating everywhere.
- 19:17SPEAKER_01: Could that patient inadvertently be addressing other entirely silent inflammatory issues lurking in their body at the exact same time?
- 19:25SPEAKER_00: Wow, like hidden joint inflammation or vascular stress.
- 19:28SPEAKER_01: Or early stage autoimmune markers, things they hadn't even recognized as a problem yet.
- 19:32SPEAKER_00: Because the diplomats don't discriminate.
- 19:36SPEAKER_01: Precisely.
- 19:37SPEAKER_00: It really makes you wonder how many secondary fires are being quietly put out while the primary target is being addressed.
- 19:43SPEAKER_01: It is a profound systemic benefit that you just do not get with a local injection.
- 19:47SPEAKER_00: So if you are navigating these treatment options, gather your latest imaging, document your treatment history, and bring these exact mechanistic questions to the specialists.
- 19:57SPEAKER_01: Ask about the needle paradox.
- 19:59SPEAKER_01: Ask about systemic signaling.
- 20:01SPEAKER_00: Take the time to understand your own biology.
- 20:03SPEAKER_00: Thank you for joining us on this deep dive into the realities of regenerative medicine.
- 20:07SPEAKER_00: We will catch you next time.